|  |
| --- |
| The PBAC agenda primarily consists of applications relating to the new listing of a drug or vaccine on the Pharmaceutical Benefits Scheme (PBS) or the National Immunisation Program (NIP).The PBAC agenda consists of the following:**1 Minutes of Previous Meeting****2 Chair’s report (verbal)****3 Matters arising from the minutes** **4 Matters arising/outstanding****5 New listing applications****6 Requests for changes to listings****7 Resubmissions****8 Pricing Matters****9 Matters relating to PBS review****10 Subcommittee and Working Party reports****11 Other business****12 Correspondence****13 Further information****14 Late papers****15 Tabled papers****16 Delistings****17 Positive recommendations not accepted by applicants after 2 years**Consumers will have the opportunity to provide comments on new drug submissions (item 5), changes to listings (item 6) and resubmissions (item 7). In many circumstances, consumers will be able to comment on items in other sections of the agenda. The submissions for which input is sought will be listed in alphabetical order by drug name. There is no provision for consumer comments to the PBAC on agenda item 8 which relates to pricing matters. Pharmaceutical benefits listed in the Schedule fall into three broad categories:*Unrestricted benefits* – have no restrictions on their therapeutic uses; *Restricted benefits* – can only be prescribed for specific therapeutic uses (noted as Restricted benefit); and *Authority required benefits* – Authority required benefits fall into two categories: 1. *Authority required benefits* require prior approval from Services Australia or the DVA (noted as Authority required)
* *Authority required (STREAMLINED) benefits* do not require prior approval from Services Australia or the DVA but require the recording of a streamlined authority code (noted as Authority required (STREAMLINED)).

Initial submissions are categorised broadly as:* *Category 1 or 2:* Submissions to list new medicines on the Schedule of Pharmaceutical Benefits or to make substantial changes to current listings are generally classified as Category 1 or 2 submissions. These submissions require presentation of an economic evaluation.
* *Category 3 or 4:* Submissions that relate to new forms of previously listed products and changes to the conditions of use e.g. change in maximum quantity/repeats or clarifying the wording of a restriction (while not altering the intended use) are considered to be Category 3 or 4 submissions. These submissions do not usually require the presentation of an economic evaluation.

Resubmissions are categorised broadly as Standard Re-entry Pathway, Early Resolution Pathway, Early Re-entry Pathway or Facilitated Resolution Pathway. Submission categories and resubmission pathways are outlined in the [Procedure Guidance](https://www.pbs.gov.au/info/industry/listing/listing-steps). The PBAC meeting agenda will be published in week 3 – and updated in week 8 (to include early pathway resubmissions, and items for review under the process for reviewing positive PBS-listing recommendations not accepted by applicants) in each PBAC cycle as per [PBS Calendar](https://www.pbs.gov.au/info/industry/useful-resources/pbs-calendar).  |

| **Drug Name, form(s), strength(s) and Sponsor, Submission type**(Drug name, form, strength, Trade name®, Sponsor, new listing/change to listing) | **Drug Type and Use**(What is the drug used to treat?) | **Listing requested by Sponsor / Purpose of Submission**(Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |
| --- | --- | --- |
| ABALOPARATIDESolution for injection 3 mg in 1.5 mL pre-filled penEladynos®THERAMEX AUSTRALIA PTY LTD(New PBS listing) | Osteoporosis | To request a General Schedule Authority Required (Telephone/Online) listing for the first line treatment of severe established osteoporosis. |
| ABIRATERONE ACETATE AND PREDNISOLONEPack containing 56 tablets abiraterone acetate 500 mg and 56 tablets prednisolone 5 mgAndriga-10ACTOR PHARMACEUTICALS PTY LTD(New PBS listing) | Castration resistant metastatic carcinoma of the prostate (mCRPC) | To request a General Schedule Authority Required (Telephone/Online) listing of a composite pack containing abiraterone acetate and prednisolone for the treatment of patients with mCRPC. |
| ACALABRUTINIBTablet 100 mgCalquence®ASTRAZENECA PTY LTD(Change to existing listing) | Mantle cell lymphoma (MCL) | To request a General Schedule Authority Required (Telephone/Online) listing in combination with bendamustine and rituximab for patients with previously untreated Stage III or IV MCL who are ineligible for stem cell transplantation. |
| AFLIBERCEPTSolution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre‑filled syringeSolution for intravitreal injection 4 mg in 100 microlitres (40 mg per mL)Afqlir®Enzeevu™SANDOZ PTY LTD(New PBS listing) | Macular oedema secondary to retinal vein occlusion (RVO)Diabetic macular oedema (DMO)Subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD) | To request General Schedule Authority Required listings of two aflibercept biosimilars for the treatment of RVO, DMO, and CNV due to AMD under the same conditions as their respective reference biologic.  |
| APOMORPHINEInjection containing apomorphine hydrochloride hemihydrate 100 mg in 20 mLMovapo® PODSTADA PHARMACEUTICALS AUSTRALIA PTY LIMITED(New PBS listing) | Parkinson disease | To request General Schedule Authority Required (STREAMLINED) and Section 100 (Highly Specialised Drugs Program) Authority Required (STREAMLINED) listings of Movapo® POD, administered via an infusion pump with a collar attachment, under the existing listings for Apomine Solution for Infusion for the treatment of Parkinson's disease. |
| ARIPIPRAZOLEPowder for injection 300 mg (as monohydrate) with diluent in pre-filled dual-chamber syringe Powder for injection 400 mg (as monohydrate) with diluent in pre-filled dual-chamber syringe Abilify Maintena®LUNDBECK AUSTRALIA PTY LTD(New PBS listing) | Schizophrenia | To request General Schedule Authority Required (STREAMLINED) listings of two new forms for the treatment of schizophrenia.  |
| BRENTUXIMAB VEDOTINPowder for I.V. infusion 50 mgAdcetris®TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD.(Change to existing listing) | Hodgkin lymphoma | Resubmission to request a Section 100 (Efficient Funding of Chemotherapy) Authority Required (Written) listing for the first line treatment of advanced Hodgkin lymphoma in combination with chemotherapy. |
| BREXPIPRAZOLETablet 500 microgramsRexulti®LUNDBECK AUSTRALIA PTY LTD(New PBS listing) | Schizophrenia | To request a General Schedule Authority Required (STREAMLINED) listing of a new strength for the treatment of schizophrenia. |
| BULEVIRTIDEPowder for injection 2 mgHepcludex®GILEAD SCIENCES PTY LTD(New PBS listing) | Chronic hepatitis D | Resubmission to request a Section 100 (Highly Specialised Drugs Program)Authority Required (STREAMLINED) listing for the treatment of chronichepatitis D. This matter was deferred at the March 2025 PBAC Meeting. |
| CABOZANTINIBTablet 20 mgTablet 40 mgTablet 60 mgCabometyx® IPSEN PTY LTD(Change to existing listing) | Pancreatic neuroendocrine tumors (pNET)Extra-pancreatic neuroendocrine tumors (epNET) | To request a General Schedule Authority Required (STREAMLINED) listing for the treatment of unresectable locally advanced or metastatic well- or moderately-differentiated pNET or epNET after prior systemic therapy. |
| CALCIPOTRIOL WITH BETAMETHASONE DIPROPIONATECream containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 gWynzora®ACTOR PHARMACEUTICALS PTY LTD(New PBS listing) | Chronic stable plaque type psoriasis vulgaris | To request a General Schedule Restricted Benefit listing for the treatment of chronic plaque type psoriasis vulgaris in patients who have not adequately responded to potent topical corticosteroid monotherapy. |
| CANNABIDIOLOral liquid 100 mg per mL, 100 mLEpidyolex®JAZZ PHARMACEUTICALS ANZ PTY LTD(Change to existing listing) | Seizures of the Lennox-Gastaut syndrome (LGS) | To request an amendment to the restriction level from Authority Required (Telephone/Online) to Authority Required (STREAMLINED) for the treatment of seizures associated with LGS. The submission also requested amendments to the clinical criteria, including the requirement for a diagnosis confirmed by an electroencephalogram and a definition of the types of seizures, and to the treatment criteria to allow prescribing by a paediatrician. |
| DONANEMABSolution concentrate for I.V. infusion 350 mg in 20 mLKisunla®ELI LILLY AUSTRALIA PTY LTD(New PBS listing) | Early symptomatic Alzheimer's disease | To request a Section 100 (Highly Specialised Drugs Program) Authority Required (Telephone/Online) listing of donanemab for the treatment of patients with early symptomatic Alzheimer's disease. |
| DURVALUMABSolution concentrate for I.V. infusion, 120 mg in 2.4 mL, 500 mg in 10mLImfinzi®ASTRAZENECA PTY LTD(Change to existing listing) | Small cell lung cancer (SCLC) | To request a Section 100 (Efficient Funding of Chemotherapy Program) Authority Required (STREAMLINED) listing for the treatment of limited-stage SCLC in patients whose disease has not progressed during or following chemoradiation therapy. |
| ENOXAPARINInjection containing enoxaparin sodium 20 mg (2,000 I.U. anti-Xa) in 0.2 mL pre-filled syringeInjection containing enoxaparin sodium 40 mg (4,000 I.U. anti-Xa) in 0.4 mL pre-filled syringeInjection containing enoxaparin sodium 60 mg (6,000 I.U. anti-Xa) in 0.6 mL pre-filled syringeInjection containing enoxaparin sodium 80 mg (8,000 I.U. anti-Xa) in 0.8 mL pre-filled syringeInjection containing enoxaparin sodium 100 mg (10,000 I.U. anti-Xa) in 1 mL pre-filled syringeInjection containing enoxaparin sodium 120 mg (12,000 I.U. anti-Xa) in 0.8 mL pre-filled syringeInjection containing enoxaparin sodium 150 mg (15,000 I.U. anti-Xa) in 1 mL pre-filled syringeEnoxaject®PHARMACOR PTY LIMITED(New PBS listing) | Prevention of venous thromboembolism (VTE) Treatment of venous thrombosisPrevention of extracorporeal thrombosis during haemodialysisTreatment of acute ST-segment elevation myocardial infarction (STEMI), non-STEMI and unstable angina | To request General Schedule Restricted Benefit listings of a new enoxaparin biosimilar under the same conditions as other enoxaparin brands for the respective forms. |
| EPLERENONETablet 25 mgTablet 50 mgInspra®VIATRIS PTY LTD(Change to existing listing) | Heart failure | To request the PBAC consider an amendment to the clinical criteria for eplerenone to align with clinical guidelines for the management of heart failure. |
| ETANERCEPTInjections 50 mg in 1 mL single use pre-filled syringes, 4Nepexto®MAXX PHARMA PTY LTD(New PBS listing) | Severe active rheumatoid arthritisSevere psoriatic arthritisAnkylosing spondylitisSevere chronic plaque psoriasisJuvenile idiopathic arthritis | To request General Schedule Authority Required and Section 100 (Highly Specialised Drugs Program) Authority Required listings of a new etanercept biosimilar under the same conditions as another biosimilar brand of etanercept in the same form for the treatment of severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, and juvenile idiopathic arthritis. |
| FUTIBATINIB Tablet 4 mg Lytgobi® TAIHO PHARMA OCEANIA PTY LTD (New PBS listing) | Bile duct cancer (cholangiocarcinoma) | Resubmission to request a General Schedule Authority Required (STREAMLINED) listing for the treatment of patients with locally advanced or metastatic cholangiocarcinoma who have previously progressed on systemic therapy and have a fibroblast growth factor receptor 2 fusion or rearrangement. |
| GIVOSIRANSolution for injection 189 mg in 1 mLGivlaari®MEDISON PHARMA AUSTRALIA PTY LIMITED(New PBS listing) | Acute hepatic porphyria (AHP) | To request a General Schedule Authority Required (Written) listing for the initial treatment and an Authority Required (STREAMLINED) listing for the continuing treatment of AHP in adults and adolescents aged 12 years and older. |
| GLOFITAMABSolution concentrate for I.V. infusion 2.5 mg in 2.5 mLSolution concentrate for I.V. infusion 10 mg in 10 mL Columvi®ROCHE PRODUCTS PTY LTD(New PBS listing) | Relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL) | To request a Section 100 (Efficient Funding of Chemotherapy Program) Authority Required (Telephone/Online) listing for the treatment of patients with RR DLBCL. |
| GUSELKUMABSolution for I.V. infusion 200 mg in 20 mL vialInjection 100 mg in 1 mL single use pre-filled penInjection 200 mg in 2 mL single use pre-filled pen,Injection 100 mg in 1 mL single use pre-filled syringeInjection 200 mg in 2 mL single use pre-filled syringe,Tremfya®JANSSEN-CILAG PTY LTD(New PBS listing) | Severe Crohn disease | To request General Schedule Authority Required (Written) listings for subcutaneous injection and a Section 100 (Highly Specialised Drug Program) Authority Required (Written) listing for I.V. infusion for the treatment of severe Crohn disease. |
| INCOBOTULINUMTOXINALyophilised powder for injection 100 unitsXeomin®MERZ AUSTRALIA PTY LTD(Change to existing listing) | Moderate to severe spasticity of the upper limbDynamic equinus foot deformity | To request a Section 100 (Botulinum Toxin Program) Authority Required (STREAMLINED) listing for the treatment of spasticity of the lower and/or upper limbs associated with cerebral palsy in patients aged 2 years and older. |
| INFLIXIMABPowder for I.V. infusion 100 mgRemsima®CELLTRION HEALTHCARE AUSTRALIA PTY LTD(New PBS listing) | Severe active rheumatoid arthritisAnkylosing spondylitisSevere psoriatic arthritisSevere chronic plaque psoriasisSevere Crohn diseaseComplex refractory fistulising Crohn DiseaseModerate to severe ulcerative colitis | To request Section 100 (Highly Specialised Drugs Program) Authority Required listings of a new infliximab biosimilar under the same conditions as other biosimilar brands of infliximab. |
| INFLUENZA VACCINEInjection 0.5 mL Fluad®Injection 0.5 mLFlucelvax®SEQIRUS (AUSTRALIA) PTY LTD(New NIP listing)WITHDRAWN | Prevention of influenza | To request National Immunisation Program (NIP) listings of inactivated trivalent influenza vaccines (TIVs), Fluad® (adjuvanted TIV) for patients aged 65 years and older, and Flucelvax® (cell-based TIV) for patients aged 6 months and older, for the prevention of influenza in the same eligible patients as the currently NIP-listed quadrivalent influenza vaccine (QIV) formulations. |
| INSULIN DEGLUDECSolution for injection 100 units per mLTresiba® Penfill®NOVO NORDISK PHARMACEUTICALS PTY. LIMITED(New PBS listing) | Type 1 diabetes mellitus (T1DM) | Resubmission to request a General Schedule Restricted Benefit listing for the treatment of T1DM. |
| LENIOLISIBTablet 70 mgJoenja®PHARMING AUSTRALIA PTY LTD(New PBS listing) | Activated PI3K delta syndrome (APDS)  | To request a Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listing for the treatment of symptomatic APDS in adults and adolescents aged 12 years and older . |
| Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1)EliglustatCapsule containing eliglustat tartrate, 100 mgCerdelga®ImiglucerasePowder for IV infusion, 400 unitsCerezyme®Taliglucerase ALFAPowder for IV infusion, 200 unitsElelyso®Velaglucerase ALFAPowder for IV infusion, 400 unitsVpriv®Various sponsors(New PBS listing) | Gaucher disease (type 1) (GD1) | To consider a referral from the LSDP Expert Panel seeking reconsideration of listing medicines for the treatment of GD1 on the PBS. |
| Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1NITISINONECapsule 2 mgCapsule 5 mgCapsule 10 mgCapsule 20 mgOral suspension 4 mg per mL, 90 mLOrfadin®A.MENARINI AUSTRALIA PTY LIMITEDTablet 2 mgTablet 5 mgTablet 10 mgNityr™ORPHARMA PTY LTD(New PBS listing) | Hereditary tyrosinaemia type 1 (HT-1) | To consider a referral from the LSDP Expert Panel seeking reconsideration of listing nitisinone for the treatment of HT-1 on the PBS. |
| METHADONETablet 5 mgMethadone-AFTAFT PHARMACEUTICALS (AU) PTY LTD(New PBS listing) | Chronic severe disabling pain | To request a Palliative Care Authority Required (Telephone/Online) listing and a General Schedule Authority Required (STREAMLINED) listing of a new strength under the same conditions as the currently listed strength of methadone tablet for the management of severe disabling pain. |
| MIRVETUXIMAB SORAVTANSINESolution for I.V. infusion 100 mg in 20 mL vialElahere®ABBVIE PTY LTD(New PBS listing) | Epithelial ovarian, fallopian tube or primary peritoneal cancer | To request a Section 100 (Efficient Funding of Chemotherapy Program) Authority Required (Telephone/Online) listing for the treatment of high grade epithelial ovarian, fallopian tube or primary peritoneal cancer in patients who have platinum-resistant disease and high folate receptor alpha (FRα) expression. |
| NEMOLIZUMABPowder for injection containing nemolizumab 30 mg with diluent in pre-filled dual-chamber penNemluvio®GALDERMA AUSTRALIA PTY LTD(New PBS listing) | Atopic dermatitis | To request a General Schedule Authority Required (Telephone/Online) listing for the treatment of patients with severe atopic dermatitis affecting the whole body, face, and/or hands.  |
| NIVOLUMABInjection concentrate for I.V. infusion 40 mg in 4 mL Injection concentrate for I.V. infusion 100 mg in 10 mL Opdivo®IPILIMUMABInjection concentrate for I.V. infusion 50 mg in 10 mLInjection concentrate for I.V. infusion 200 mg in 40 mLYervoy®BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD(Change to existing listing) | Advanced (unresectable) Barcelona Clinic Liver Cancer Stage A, Stage B or Stage C hepatocellular carcinoma (HCC) | To request a Section 100 (Efficient Funding of Chemotherapy Program) Authority Required (STREAMLINED) listing for the first line treatment of advanced (unresectable) HCC. |
| NIVOLUMABInjection concentrate for I.V. infusion 40 mg in 4 mL Injection concentrate for I.V. infusion 100 mg in 10 mL Opdivo®IPILIMUMABInjection concentrate for I.V. infusion 50 mg in 10 mLYervoy®BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD(Change to existing listing) | Unresectable or metastatic colorectal cancer (mCRC) | To request a Section 100 (Efficient Funding of Chemotherapy Program) Authority Required (STREAMLINED) listing for the first line treatment of microsatellite instability high or mismatch repair deficient mCRC. |
| NIVOLUMABInjection concentrate for I.V. infusion 40 mg in 4 mLInjection concentrate for I.V. infusion 100 mg in 10 mLOpdivo®IPILIMUMABInjection concentrate for I.V. infusion 50 mg in 10 mLInjection concentrate for I.V. infusion 200 mg in 40 mLYervoy®Bristol-Myers Squibb Australia Pty Ltd(Change to existing listing) | Unresectable advanced and metastatic cancer | To consider a proposal for an expanded listing to facilitate broad access for unresectable advanced and metastatic cancer.  |
| OCRELIZUMABSolution for subcutaneous injection 920 mg in 23 mL Ocrevus®ROCHE PRODUCTS PTY LTD(New PBS listing) | Relapsing-remitting multiple sclerosis (RRMS) | To request Section 100 (Highly Specialised Drugs Program) Authority Required (STREAMLINED) listings of a new form for the treatment of RRMS.  |
| ODEVIXIBATCapsule 200 microgramsCapsule 400 microgramsCapsule 600 microgramsCapsule 1200 microgramsBylvay®IPSEN PTY LTD(New PBS listing) | Progressive familial intrahepatic cholestasis (PFIC) | Resubmission to request a Section 100 (Highly Specialised Drugs Program) Authority Required (STREAMLINED) listing for the treatment of PFIC. This matter was deferred at the March 2025 PBAC Meeting. |
| OSIMERTINIBTablet 40 mgTablet 80 mgTagrisso®ASTRAZENECA PTY LTD(Change to existing listing) | Unresectable locally advanced (Stage III) non-small cell lung cancer (NSCLC) | To request a General Schedule Authority Required (Telephone/Online) listing of osimertinib as monotherapy for the treatment of patients with unresectable, locally advanced (Stage III) epidermal growth factor receptor (EGFR) mutation positive NSCLC whose disease has not progressed during or following platinum-based chemoradiation therapy. |
| PALIPERIDONEI.M. injection (modified release) 25 mg (as palmitate) in pre-filled syringeI.M. injection (modified release) 50 mg (as palmitate) in pre-filled syringeI.M. injection (modified release) 75 mg (as palmitate) in pre-filled syringeI.M. injection (modified release) 100 mg (as palmitate) in pre-filled syringeI.M. injection (modified release) 150 mg (as palmitate) in pre-filled syringePaljuna MonthlyJUNO PHARMACEUTICALS PTY LTD(New PBS listing) | Schizophrenia | To request General Schedule Authority Required (STREAMLINED) listings of a new generic brand of paliperidone monthly long-acting injection for the maintenance treatment of schizophrenia.  |
| PALOPEGTERIPARATIDESolution for subcutaneous injection 168 micrograms in 0.56 mL pre-filled penSolution for subcutaneous injection 294 micrograms in 0.98 mL pre-filled penSolution for subcutaneous injection 420 micrograms in 1.4 mL pre-filled penYorvipath®SPECIALISED THERAPEUTICS PHARMA PTY LTD(New PBS listing) | Chronic hypoparathyroidism | Resubmission to request a General Schedule Authority Required (Telephone/Online) listing for the treatment of chronic hypoparathyroidism. |
| PEGUNIGALSIDASE ALFASolution for I.V. injection 20 mg in 10 mL vialElfabrio®CHIESI AUSTRALIA PTY LTD(New PBS listing) | Fabry disease | To request a Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listing for the treatment of Fabry disease. |
| PEMBROLIZUMABSolution concentrate for I.V. infusion 100 mg in 4 mLKeytruda®MERCK SHARP & DOHME (AUSTRALIA) PTY LTD(Change to existing listing) | Endometrial cancer | To request a Section 100 (Efficient Funding of Chemotherapy Program) Authority Required (STREAMLINED) listing for pembrolizumab in combination with platinum-based chemotherapy, followed by pembrolizumab monotherapy, for primary advanced or recurrent endometrial cancer, regardless of mismatch repair status. |
| PEMBROLIZUMABSolution concentrate for I.V. infusion 100 mg in 4 mLKeytruda®Merck Sharp & Dohme (Australia) Pty Ltd(Change to existing listing) | Unresectable advanced and metastatic cancer | To consider a proposal for an expanded listing to facilitate broad access for unresectable advanced and metastatic cancer. |
| PIOGLITAZONETablet 15 mg (as hydrochloride)Tablet 30 mg (as hydrochloride)Tablet 45 mg (as hydrochloride)Actos®CELLTRION HEALTHCARE AUSTRALIA PTY LTD(New PBS listing)TO BE CONSIDERED AT THE MAY 2025 PBAC MEETING | Type 2 diabetes mellitus (T2DM) | To request General Schedule Restricted Benefit listings for a new pack size of pioglitazone (Actos®), with an increased maximum quantity across all currently PBS-listed strengths of pioglitazone for the treatment of T2DM. |
| RESPIRATORY SYNCYTIAL VIRUS VACCINEPowder and suspension for injection (0.5 mL)Arexvy®GLAXOSMITHKLINE AUSTRALIA PTY LTD(New NIP listing) | Prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) | Resubmission to request a National Immunisation Program (NIP) listing for the prevention of lower respiratory tract disease caused by RSV in older adults. |
| RIBOCICLIBTablet 200 mgKisqali®NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED(Change to existing listing) | Hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) early breast cancer | To request a General Schedule Authority Required (Telephone/Online) listing for the treatment of patients with HR+/HER2- resected, Stage II or III early breast cancer at high risk of recurrence. |
| SELADELPARCapsule 10 mgLivdelzi®GILEAD SCIENCES PTY LTD(New PBS listing) | Primary biliary cholangitis (PBC) | To request a General Schedule Authority Required (STREAMLINED) listing for the treatment of PBC in patients who have had an inadequate response to first line therapy with ursodeoxycholic acid (UDCA) or are intolerant to UDCA. |
| TACROLIMUSOintment 1 mg per g, 30 gaZematop®ARROTEX PHARMACEUTICALS PTY LTD(New PBS listing) | Atopic dermatitis | To request a General Schedule Authority Required (STREAMLINED) listing for the treatment of moderate to severe atopic dermatitis. |
| TARLATAMAB Powder for injection 10 mg Imdelltra® AMGEN AUSTRALIA PTY LTD (New PBS listing)WITHDRAWN | Small cell lung cancer | To request a Section 100 (Efficient Funding of Chemotherapy Program) Authority Required (STREAMLINED) listing for the treatment of patients with extensive-stage small-cell lung cancer with disease progression after platinum-based chemotherapy and at least one other line of therapy (i.e. third-line therapy or thereafter). |
| TERIPARATIDEInjection 250 micrograms per mL, 2.4 mL in multi-dose pre-filled penRitosa®SUN PHARMA ANZ PTY LTD(New PBS listing) | Osteoporosis | To request a General Schedule Authority Required (STREAMLINED) listing under the same conditions as the currently listed brands of teriparatide for the treatment of severe established osteoporosis. |
| TIRZEPATIDESolution for injection 2.5 mg in 0.5 mL vial/pre-filled penSolution for injection 5 mg in 0.5 mL vial/pre-filled penSolution for injection 7.5 mg in 0.5 mL vial/pre-filled penSolution for injection 10 mg in 0.5 mL vial/pre-filled penSolution for injection 12.5 mg in 0.5 mL vial/pre-filled penSolution for injection 15 mg in 0.5 mL vial/pre-filled penMounjaro®Injection 4.17 milligrams per mL (2.5 mg per dose) in multi-dose pre-filled pen, 4 doseInjection 8.33 milligrams per mL (5 mg per dose) in multi-dose pre-filled pen, 4 dosesInjection 12.5 milligrams per mL (7.5 mg per dose) in multi-dose pre-filled pen, 4 dosesInjection 16.67 milligrams per mL (10 mg per dose) in multi-dose pre-filled pen, 4 dosesInjection 20.83 milligrams per mL (12.5 mg per dose) in multi-dose pre-filled pen, 4 dosesInjection 25 milligrams per mL (15 mg per dose) in multi-dose pre-filled pen, 4 dosesMounjaro® KwikPen®ELI LILLY AUSTRALIA PTY LTD(New PBS listing) | Type 2 diabetes mellitus (T2DM) | Resubmission to request a General Schedule Authority Required (Telephone/Online) listing for the treatment of adults with inadequately controlled T2DM. |
| VANZACAFTOR WITH TEZACAFTOR AND WITH DEUTIVACAFTORPack containing 84 tablets vanzacaftor 4 mg with tezacaftor 20 mg and with deutivacaftor 50 mgPack containing 56 tablet vanzacaftor 10 mg with tezacaftor 50 mg and with deutivacaftor 125 mgAlyftrek®VERTEX PHARMACEUTICALS PTY LTD(New PBS listing) | Cystic fibrosis | To request a Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listing for the treatment of cystic fibrosis in patients who are aged 6 years and older and who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. |
| VELMANASE ALPHAPowder for I.V. infusion 10 mgLamzede®CHIESI AUSTRALIA PTY LTD(New PBS listing) | Alpha- mannosidosis | To request a Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listing as an enzyme replacement therapy for the treatment of non-neurological manifestations in patients with alpha-mannosidosis. |
| VORASIDENIBTablet 10 mgTablet 40 mgVoranigo®SERVIER LABORATORIES (AUST.) PTY. LTD.(New PBS listing) | Astrocytoma or oligodendroglioma | To request a General Schedule Authority Required (STREAMLINED) listing for the treatment of isocitrate dehydrogenase-mutant astrocytoma or oligodendroglioma. |
| ATEZOLIZUMABSolution concentrate for I.V. infusion 840 mg in 14 mL Solution concentrate for I.V. infusion 1200 mg in 20 mL Tecentriq®Solution for subcutaneous injection 1875 mg in 15 mLTecentriq® SCROCHE PRODUCTS PTY LTD(Sub-committee report DUSC analysis) | Hepatocellular carcinoma | To assess the utilisation of PBS listed atezolizumab for advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma. |
| CEMIPLIMABSolution concentrate for I.V. infusion 350 mg in 7 mLLibtayo®Medison Pharma Australia Pty Ltd(Sub-committee report DUSC analysis) | Metastatic or locally advanced cutaneous squamous cell carcinoma | To assess the utilisation of PBS listed cemiplimab for metastatic or locally advanced cutaneous squamous cell carcinoma. |
| NIVOLUMABInjection concentrate for I.V. infusion 40 mg in 4 mL Injection concentrate for I.V. infusion 100 mg in 10 mLOpdivo®Bristol-Myers Squibb Australia Pty Ltd(Sub-committee report DUSC analysis) | Advanced or metastatic gastro-oesophageal cancers | To assess the utilisation of PBS listed nivolumab for advanced or metastatic gastro-oesophageal cancers.  |
| NUSINERSENSolution for injection 12 mg in 5 mLSpinraza®Biogen Australia Pty Ltd(Sub-committee report DUSC analysis) | Spinal muscular atrophy  | To assess the utilisation of PBS listed nusinersen for spinal muscular atrophy in adult patients.  |
| Transition existing quadrivalent influenza formulations to trivalent formulationsInjection (0.5 mL)Various brandsVarious sponsors(Other matters) | Prevention of influenza | To request advice from the PBAC on varying the *National Health (Immunisation Program – Designated Vaccines) Determination 2014 (No. 1)* to transition existing quadrivalent influenza vaccine formulations to trivalent formulations. |
| TRIGLYCERIDES, MEDIUM CHAINOil 500 mL (MCT Oil)MCT OilNUTRICIA AUSTRALIA PTY LIMITED(Other matters) | Chylous ascitesChylothoraxFat malabsorptionHyperlipoproteinaemia type 1Intractable childhood epilepsyCerebrospinal fluid glucose transporter defectLong chain fatty acid oxidation disorders | To request an increase in the maximum quantity of MCT Oil for all PBS-listed indications. |
| TRIGLYCERIDES - MEDIUM CHAIN, FORMULAOral powder 400 g (Monogen)Monogen®NUTRICIA AUSTRALIA PTY LIMITED(Other matters) | Dietary management of conditions requiring a source of medium chain triglyceridesHyperlipoproteinaemia type 1Long chain fatty acid oxidation disordersChylous ascitesChylothorax | To request an increase in the maximum quantity of Monogen for all PBS-listed indications. |
| CARMELLOSE WITH GLYCEROL AND HYALURONIC ACIDEye drops containing carmellose sodium 5 mg with glycerol 9 mg and sodium hyaluronate 1 mg per mLOptive Fusion®  ABBVIE PTY LTD (Review of positive PBAC recommendations not accepted by applicants) | Severe dry eye syndrome | To request the PBAC review its May 2023 recommendation that has not yet been accepted by the applicant. |
| GALCANEZUMABInjection 120 mg in 1 mL pre-filled pen Emgality® ELI LILLY AUSTRALIA PTY LTD(Review of positive PBAC recommendations not accepted by applicants) | Treatment-resistant high frequency episodic migraine | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |
| HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR Eye drops containing sodium hyaluronate 1.5 mg per mL with polyethylene glycol 400, propylene glycol and hydroxypropyl guar, 10 mLSystane® HydrationALCON LABORATORIES (AUSTRALIA) PTY LTD(Review of positive PBAC recommendations not accepted by applicants) | Severe dry eye syndrome | To request the PBAC review its May 2023 recommendation that has not yet been accepted by the applicant. |
| MIRIKIZUMABSolution concentrate for I.V. infusion 300 mg in 15 mLSolution for injection 100 mg in 1 mL pre-filled penOmvoh® ELI LILLY AUSTRALIA PTY LTD(Review of positive PBAC recommendations not accepted by applicants) | Ulcerative colitis | To request the PBAC review its July 2023 recommendation that has not yet been accepted by the applicant. |
| MOBOCERTINIBCapsule 400 mgExkivity® TAKEDA PHARMACEUTICALS AUSTRALIA PTY LTD(Review of positive PBAC recommendations not accepted by applicants) | Non-small cell lung cancer | To request the PBAC review its July 2023 recommendation that has not yet been accepted by the applicant. |
| SECUKINUMABSolution for injection 300 mg in 2 mL pre-filled penSolution for injection 300 mg in 2 mL pre-filled syringeCosentyx® NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED(Review of positive PBAC recommendations not accepted by applicants) | Non-radiographic axial spondyloarthritisSevere active psoriatic arthritisSevere psoriatic arthritisAnkylosing spondylitisActive ankylosing spondylitisSevere chronic plaque psoriasis | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |
| SOMAPACITANInjection 5 mg in 1.5 mL pre-filled penInjection 10 mg in 1.5 mL pre-filled penInjection 15 mg in 1.5 mL pre-filled penSogroya® NOVO NORDISK PHARMACEUTICALS PTY LIMITED(Review of positive PBAC recommendations not accepted by applicants)WITHDRAWN | Paediatric patients with growth hormone deficiency | To request the PBAC review its July 2023 recommendation that has not yet been accepted by the applicant. |
| SOMAPACITANInjection 10 mg in 1.5 mL pre-filled penSogroya® NOVO NORDISK PHARMACEUTICALS PTY LIMITED(Review of positive PBAC recommendations not accepted by applicants) | Adult-onset growth hormone deficiency | To request the PBAC review its March 2022 recommendation that has not yet been accepted by the applicant. |
| Review of PBS-listed medicines for nurse practitioner prescribingVarious forms and strengthsVarious brandsVarious sponsors(Other matters) | Various | To request the PBAC consider a tranche of PBS-listed medicines which do not include nurse practitioners as authorised prescribers but may be suitable for prescribing by these health professionals. |

Version 5

Items added or amended

1. ARIPIPRAZOLE (Abilify Maintena®) – Form(s) amended
2. BULEVIRTIDE (Hepcludex®) – Added
3. EPLERENONE (Inspra®) – Sponsor amended
4. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) – Forms and trade names amended
5. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 – Drug names, forms, and trade names amended
6. ODEVIXIBAT (Bylvay®) – Added
7. Review of PBS-listed medicines for nurse practitioner prescribing (Various brands) – Added
8. SOMAPACITAN (Sogroya®, Paediatric patients with growth hormone deficiency) – Review of positive PBAC recommendations not accepted by applicants – Withdrawn
9. TARLATAMAB (Imdelltra®) – Withdrawn

Items added or amended previously

1. CARMELLOSE WITH GLYCEROL AND HYALURONIC ACID (Optive Fusion®) – Review of positive PBAC recommendations not accepted by applicants – Added
2. CANNABIDIOL (Epidyolex®) – Purpose of submission amended
3. FUTIBATINIB (Lytgobi®) – Added
4. GALCANEZUMAB (Emgality®) – Review of positive PBAC recommendations not accepted by applicants – Added
5. HYALURONIC ACID WITH POLYETHYLENE GLYCOL 400 WITH PROPYLENE GLYCOL WITH HYDROXYPROPYL GUAR (Systane® Hydration) – Review of positive PBAC recommendations not accepted by applicants – Added
6. INFLUENZA VACCINE (Fluad®, Flucelvax®) – Withdrawn
7. Life Saving Drugs Program (LSDP) medicines for Gaucher disease (type 1) – Added
8. Life Saving Drugs Program (LSDP) medicines for hereditary tyrosinaemia type 1 – Added
9. MIRIKIZUMAB (Omvoh®) – Review of positive PBAC recommendations not accepted by applicants – Added
10. MOBOCERTINIB (Exkivity®) – Review of positive PBAC recommendations not accepted by applicants – Added
11. NIVOLUMAB (Opdivo®) + IPILIMUMAB (Yervoy®) – Unresectable advanced and metastatic cancer – Added
12. PALOPEGTERIPARATIDE (Yorvipath®) – Added
13. PEMBROLIZUMAB (Keytruda®) – Unresectable advanced and metastatic cancer – Added
14. PIOGLITAZONE (Actos®) – To be considered at the May 2025 PBAC meeting
15. SECUKINUMAB (Cosentyx®) – Review of positive PBAC recommendations not accepted by applicants – Added
16. SOMAPACITAN (Sogroya®, Paediatric patients with growth hormone deficiency) – Review of positive PBAC recommendations not accepted by applicants – Added
17. SOMAPACITAN (Sogroya®, Adult-onset growth hormone deficiency) – Review of positive PBAC recommendations not accepted by applicants – Added
18. Transition existing quadrivalent influenza vaccine formulations to trivalent formulations (Various brands) – Added
19. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) – Form amended
20. TRIGLYCERIDES, MEDIUM CHAIN (MCT Oil) – Submission type amended
21. TRIGLYCERIDES - MEDIUM CHAIN, FORMULA (Monogen®) – Added